An Orchestrated Response To Tumor Signals
By Macrophages and Mesenchymal Stem
Cells Potentiates Interleukin-6 Secretion In
Glioblastoma

• Authors: Kevin Anton , John Glod
• Languages of publication: EN

Abstracts

EN

The tumor microenvironment plays a critical
role in the survival, growth, invasion, and metastasis
of solid tumors. However, the mechanisms by which it
influences these aspects of tumor progression remain
incompletely characterized. In this study, we show that
human glioblastoma cells secrete soluble factors that
alter the phenotype and cytokine secretion profile of
both macrophages and mesenchymal stem cells (MSCs).
Macrophages and MSCs respond to tumor-secreted factors
by increasing the release of interleukin-6 (IL-6) and this
response is potentiated when macrophages and MSCs
are combined in co-culture. In glioblastoma, IL-6 has
been associated with tumor cell invasion, angiogenesis,
tumor cell proliferation, immune suppression, and poor
prognosis. Our results suggest that the orchestrated
response of macrophages and stromal elements to
neoplastic cells enhances tumor progression through the
release of soluble factors.

Keywords

EN

Mesenchymal stem cell (MSC); Macrophage; Interleukin-6 (IL-6); Inflammatory; Microenvironment; Chemotaxis

• Publisher: De Gruyter Open
• Journal: Cell death in therapy
• Year: 2014
• Volume: 1
• Issue: 1

Dates

online

10 - 12 - 2014

received

25 - 8 - 2014

accepted

6 - 10 - 2014

Contributors

author

Kevin Anton

• Departments of Pharmacology, The Cancer Institute
  of New Jersey, Robert Wood Johnson Medical School, University of
  Medicine and Dentistry of New Jersey, New Brunswick, NJ USA

author

John Glod

• Departments of Pediatrics and
  Pharmacology, The Cancer Institute of New Jersey, Robert Wood
  Johnson Medical School, University of Medicine and Dentistry of
  New Jersey
• Pediatric Oncology Branch, National Cancer Institute,
  Bethesda

References

• [1] Wheeler SE, Shi H, Lin F et al. Enhancement of head andneck squamous cell carcinoma proliferation, invasion, andmetastasis by tumor-associated fibroblasts in preclinicalmodels. Head Neck. 2013.
• [2] Anton K, Glod J. Targeting the tumor stroma in cancer therapy.Curr Pharm Biotechnol. 2009;10:185-191.[WoS][Crossref]
• [3] Horimoto Y, Polanska UM, Takahashi Y et al. Emerging roles ofthe tumor-associated stroma in promoting tumor metastasis.Cell Adh Migr. 2012;6:193-202.[Crossref][WoS]
• [4] Rossi ML, Hughes JT, Esiri MM et al. Immunohistological studyof mononuclear cell infiltrate in malignant gliomas. ActaNeuropathol. 1987;74:269-277.[Crossref]
• [5] Frei K, Piani D, Malipiero UV et al. Granulocyte-macrophagecolony-stimulating factor (GM-CSF) production by glioblastomacells. Despite the presence of inducing signals GM-CSF is notexpressed in vivo. J Immunol. 1992;148:3140-3146.
• [6] Nishie A, Ono M, Shono T et al. Macrophage infiltration andheme oxygenase-1 expression correlate with angiogenesis inhuman gliomas. Clin Cancer Res. 1999;5:1107-1113.
• [7] Gouon-Evans V, Lin EY, Pollard JW. Requirement of macrophagesand eosinophils and their cytokines/chemokines for mammarygland development. Breast Cancer Res. 2002;4:155-164.[Crossref]
• [8] Zhang BC, Gao J, Wang J et al. Tumor-associated macrophagesinfiltration is associated with peritumoral lymphangiogenesisand poor prognosis in lung adenocarcinoma. Med Oncol.2011;28:1447-1452.[Crossref][WoS]
• [9] Luo Y, Zhou H, Krueger J et al. Targeting tumor-associatedmacrophages as a novel strategy against breast cancer. J ClinInvest. 2006;116:2132-2141.[Crossref]
• [10] Sierra JR, Corso S, Caione L et al. Tumor angiogenesis andprogression are enhanced by Sema4D produced by tumorassociatedmacrophages. J Exp Med. 2008;205:1673-1685.[WoS]
• [11] Mills CD, Kincaid K, Alt JM et al. M-1/M-2 macrophages and theTh1/Th2 paradigm. J Immunol. 2000;164:6166-6173.
• [12] Laoui D, Van Overmeire E, De Baetselier P et al. FunctionalRelationship between Tumor-Associated Macrophages andMacrophage Colony-Stimulating Factor as Contributors toCancer Progression. Frontiers in immunology. 2014;5:489.
• [13] Martinez FO, Gordon S. The M1 and M2 paradigm ofmacrophage activation: time for reassessment. F1000primereports. 2014;6:13.
• [14] Van Overmeire E, Laoui D, Keirsse J et al. Mechanisms drivingmacrophage diversity and specialization in distinct tumormicroenvironments and parallelisms with other tissues.Frontiers in immunology. 2014;5:127.[WoS]
• [15] Mishra PJ, Humeniuk R, Medina DJ et al. Carcinoma-associatedfibroblast-like differentiation of human mesenchymal stemcells. Cancer Res. 2008;68:4331-4339.[Crossref]
• [16] Jia CC, Wang TT, Liu W et al. Cancer-associated fibroblasts fromhepatocellular carcinoma promote malignant cell proliferationby HGF secretion. PLoS One. 2013;8:e63243.
• [17] Kim SH, Choe C, Shin YS et al. Human lung cancer-associatedfibroblasts enhance motility of non-small cell lung cancer cellsin co-culture. Anticancer Res. 2013;33:2001-2009.
• [18] Yu B, Chen X, Li J et al. Stromal fibroblasts in the microenvironmentof gastric carcinomas promote tumor metastasis viaupregulating TAGLN expression. BMC Cell Biol. 2013;14:17.[Crossref][WoS]
• [19] Bababeygy SR, Cheshier SH, Hou LC et al. Hematopoietic stemcell-derived pericytic cells in brain tumor angio-architecture.Stem Cells Dev. 2008;17:11-18.[Crossref][WoS]
• [20] Comito G, Giannoni E, Segura CP et al. Cancer-associatedfibroblasts and M2-polarized macrophages synergize duringprostate carcinoma progression. Oncogene. 2013.[WoS]
• [21] Anton K, Banerjee D, Glod J. Macrophage-AssociatedMesenchymal Stem Cells Assume an Activated, Migratory,Pro-Inflammatory Phenotype with Increased IL-6 and CXCL10Secretion. PLoS One. 2012;7:e35036.
• [22] Komohara Y, Ohnishi K, Kuratsu J et al. Possible involvement ofthe M2 anti-inflammatory macrophage phenotype in growth ofhuman gliomas. J Pathol. 2008;216:15-24.[WoS]
• [23] Pyonteck SM, Akkari L, Schuhmacher AJ et al. CSF-1R inhibitionalters macrophage polarization and blocks glioma progression.Nat Med. 2013;19:1264-1272.[Crossref][WoS]
• [24] Balyasnikova IV, Ferguson SD, Sengupta S et al. Mesenchymalstem cells modified with a single-chain antibody againstEGFRvIII successfully inhibit the growth of human xenograftmalignant glioma. PLoS One. 2010;5:e9750.
• [25] Roger M, Clavreul A, Venier-Julienne MC et al. Mesenchymalstem cells as cellular vehicles for delivery of nanoparticles tobrain tumors. Biomaterials. 2010;31:8393-8401.[WoS][Crossref]
• [26] Hai C, Jin YM, Jin WB et al. Application of mesenchymal stemcells as a vehicle to deliver replication-competent adenovirusfor the treatment of malignant glioma. Chin J Cancer. 2012.[WoS]
• [27] Chang CY, Li MC, Liao SL et al. Prognostic and clinicalimplication of IL-6 expression in glioblastoma multiforme. J ClinNeurosci. 2005;12:930-933.
• [28] Kudo M, Jono H, Shinriki S et al. Antitumor effect of humanizedanti-interleukin-6 receptor antibody (tocilizumab) on gliomacell proliferation. Laboratory investigation. J Neurosurg.2009;111:219-225.[WoS]
• [29] Wang H, Lathia JD, Wu Q et al. Targeting interleukin 6 signalingsuppresses glioma stem cell survival and tumor growth. StemCells. 2009;27:2393-2404.[WoS]
• [30] Mishra PJ, Banerjee D. Activation and differentiation ofmesenchymal stem cells. Methods Mol Biol. 2011;717:245-253.

Identifiers

DOI

10.2478/cdth-2014-0001